Whitman-Walker Health highlights the importance of PrEP in HIV prevention and encourages collective action to increase access ...

Global health leaders and advocates challenged attendees of IAS to support the work of the partnerships that are creating patient-focused innovations for HIV prevention and treatment.

The World Health Organization on Monday recommended Gilead's lenacapavir, a twice-yearly injection, as a tool to prevent HIV infection.

ViiV Healthcare, the HIV-focused joint venture majority owned by GSK , said on Monday it has expanded its licensing deal with ...

The Food and Drug Administration (FDA) has accepted the New Drug Application for doravirine/islatravir (DOR/ISL) for adults with virologically-suppressed HIV-1 infection.

WHO has officially recommended twice-yearly injectable lenacapavir for HIV prevention, marking a major shift in global HIV strategy with potential to curb new infections and improve access worldwide.

This isn’t about managing the AIDS pandemic. It’s about ending it — and letting a new generation grow and thrive free of its ...

Lenacapavir offers twice-yearly HIV prevention with near-complete protection in clinical trials. Clinical trials show ...

From the first reported case of AIDS to the present, what is the history of HIV-AIDS and are there parallels to the COVID-19 pandemic?

The Food and Drug Administration (FDA) recently approved lenacapavir for HIV prevention in both men and women. Many experts believe this twice a year treatment could be a game changer in the fight ...

According to a phase 1 trial, the experimental HIVconsvX vaccine is safe and immunogenic among sub-Saharan African participants who bear the highest burden of HIV-1.

Researchers have identified a never-before-seen mechanism that enables HIV-1 to evade the body's natural defenses and use it to support its survival and replication. The 'loophole' is a biological ...